BeyondSpring (BYSI) Competitors $1.76 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.74 -0.01 (-0.85%) As of 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BYSI vs. ABEO, CGC, BNTC, ALDX, ZYBT, INBX, CADL, IMAB, RCKT, and AMRNShould you be buying BeyondSpring stock or one of its competitors? The main competitors of BeyondSpring include Abeona Therapeutics (ABEO), Canopy Growth (CGC), Benitec Biopharma (BNTC), Aldeyra Therapeutics (ALDX), Zhengye Biotechnology (ZYBT), Inhibrx Biosciences (INBX), Candel Therapeutics (CADL), I-Mab (IMAB), Rocket Pharmaceuticals (RCKT), and Amarin (AMRN). These companies are all part of the "pharmaceutical products" industry. BeyondSpring vs. Its Competitors Abeona Therapeutics Canopy Growth Benitec Biopharma Aldeyra Therapeutics Zhengye Biotechnology Inhibrx Biosciences Candel Therapeutics I-Mab Rocket Pharmaceuticals Amarin Abeona Therapeutics (NASDAQ:ABEO) and BeyondSpring (NASDAQ:BYSI) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, media sentiment, institutional ownership and profitability. Which has stronger earnings and valuation, ABEO or BYSI? BeyondSpring has lower revenue, but higher earnings than Abeona Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAbeona Therapeutics$3.50M105.93-$63.73M$0.7010.33BeyondSpring$1.75M40.56-$11.12MN/AN/A Do insiders and institutionals have more ownership in ABEO or BYSI? 80.6% of Abeona Therapeutics shares are held by institutional investors. Comparatively, 40.3% of BeyondSpring shares are held by institutional investors. 6.9% of Abeona Therapeutics shares are held by insiders. Comparatively, 29.3% of BeyondSpring shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more risk and volatility, ABEO or BYSI? Abeona Therapeutics has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500. Comparatively, BeyondSpring has a beta of 0.26, indicating that its stock price is 74% less volatile than the S&P 500. Is ABEO or BYSI more profitable? Abeona Therapeutics' return on equity of 89.05% beat BeyondSpring's return on equity.Company Net Margins Return on Equity Return on Assets Abeona TherapeuticsN/A 89.05% 45.64% BeyondSpring N/A N/A N/A Do analysts rate ABEO or BYSI? Abeona Therapeutics presently has a consensus price target of $19.50, suggesting a potential upside of 169.71%. Given Abeona Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Abeona Therapeutics is more favorable than BeyondSpring.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Abeona Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00BeyondSpring 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer ABEO or BYSI? In the previous week, Abeona Therapeutics had 23 more articles in the media than BeyondSpring. MarketBeat recorded 24 mentions for Abeona Therapeutics and 1 mentions for BeyondSpring. BeyondSpring's average media sentiment score of 1.34 beat Abeona Therapeutics' score of 0.49 indicating that BeyondSpring is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Abeona Therapeutics 2 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral BeyondSpring 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryAbeona Therapeutics beats BeyondSpring on 10 of the 13 factors compared between the two stocks. Get BeyondSpring News Delivered to You Automatically Sign up to receive the latest news and ratings for BYSI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding BYSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BYSI vs. The Competition Export to ExcelMetricBeyondSpringMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$70.99M$3.11B$5.76B$9.59BDividend YieldN/A2.23%4.41%4.09%P/E RatioN/A20.8831.1026.05Price / Sales40.56392.41470.24120.75Price / CashN/A43.1937.7358.48Price / Book-4.008.129.536.61Net Income-$11.12M-$54.72M$3.26B$265.56M7 Day Performance-12.87%2.62%2.11%1.98%1 Month Performance-5.88%7.63%5.12%1.33%1 Year Performance-7.85%13.11%31.25%21.15% BeyondSpring Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BYSIBeyondSpringN/A$1.76flatN/A-6.9%$70.99M$1.75M0.0080Positive NewsGap UpABEOAbeona Therapeutics4.4467 of 5 stars$6.39+1.7%$19.25+201.5%+35.7%$326.45M$3.50M-5.0290News CoverageAnalyst RevisionCGCCanopy Growth0.7855 of 5 stars$1.59+0.3%N/A-80.6%$325.16M$225.65M-0.523,150Positive NewsShort Interest ↑High Trading VolumeBNTCBenitec Biopharma1.3997 of 5 stars$12.30+3.3%$26.00+111.5%+41.7%$324.03M$80K-8.1720News CoverageALDXAldeyra Therapeutics2.0925 of 5 stars$5.40+2.8%$9.50+76.1%+9.7%$321.96MN/A-6.3210ZYBTZhengye BiotechnologyN/A$6.79+26.2%N/AN/A$320.28M$25.53M0.00278News CoveragePositive NewsGap DownINBXInhibrx Biosciences1.7406 of 5 stars$21.74+1.6%N/A+85.1%$314.80M$200K0.19166Analyst ForecastShort Interest ↓CADLCandel Therapeutics2.6155 of 5 stars$6.29+1.4%$22.00+249.5%+10.1%$314.58M$120K-4.6960IMABI-Mab3.3403 of 5 stars$3.82-1.8%$6.00+57.1%+292.5%$310.11M$3.89M0.00380News CoverageEarnings ReportAnalyst ForecastRCKTRocket Pharmaceuticals4.8814 of 5 stars$2.87-1.8%$16.33+469.5%-81.4%$309.13MN/A-1.14240Analyst ForecastAnalyst RevisionAMRNAmarin0.294 of 5 stars$14.75-1.3%$12.00-18.6%+22.1%$305.47M$228.61M-4.02360Positive News Related Companies and Tools Related Companies ABEO Competitors CGC Competitors BNTC Competitors ALDX Competitors ZYBT Competitors INBX Competitors CADL Competitors IMAB Competitors RCKT Competitors AMRN Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BYSI) was last updated on 8/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredA grave, grave error.Nvidia just shattered records—hitting $4 trillion in valuation faster than any company in history. But one ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BeyondSpring Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BeyondSpring With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access